Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients

Area of Science:

• Cardiovascular Medicine
• Pharmacoeconomics
• Health Policy

Background:

• The American College of Cardiology suggests statin therapy for adults aged 45-70 with normal cholesterol, diabetes, or high atherosclerotic cardiovascular disease (ASCVD) risk (>7.5%).
• While cost-effective, the high budget impact of this policy may hinder widespread adoption and clinical effectiveness.
• This study addresses the potential limitations of current statin therapy guidelines due to cost.

Purpose of the Study:

• To evaluate if using a significantly less expensive statin, Simvastatin, for a broader population can yield superior overall outcomes for the intended use population (IUP) under a fixed budget.
• To compare the population-level effectiveness of Simvastatin versus branded Rosuvastatin.
• To assess the impact of statin choice on major adverse cardiovascular events (MACE) within budgetary limitations.

Main Methods:

• A health economic model was developed to compare outcomes for the entire IUP.
• The model simulated the effects of branded Rosuvastatin versus Simvastatin on MACE.
• Major adverse cardiovascular events (MACE) included cardiovascular death, stroke, myocardial infarction, and hospitalizations for revascularization or unstable angina.

Main Results:

• Simvastatin use was associated with the prevention of 311,698 MACE.
• Branded Rosuvastatin use prevented 6,571 MACE.
• Generic Rosuvastatin use prevented 83,120 MACE.

Conclusions:

• Within budget constraints, Simvastatin use resulted in a 47-fold greater prevention of MACE for the entire IUP compared to branded Rosuvastatin.
• The findings suggest Simvastatin may be a more effective population-level strategy for cardiovascular risk reduction under budget constraints.
• Consideration of Simvastatin is recommended for initiating statin therapy in the target population to maximize public health benefits within financial limitations.